197-207 (2 ) 10 1389 -. 2 1 1* :.. 352 :... (TG). (). -.(r= 0/95) :. TG. NCEP-ATP-III. :. () : -1-2 1593748711 : ronakn2000@yahoo.com : 88942661-5 09124135284
... : 198.[4]. 1990 -. C.[4]. NCEP.[4]... 12 18.... (NCEP-ATP-III) III ) (. ().[1 2] NCEP-) (ATP III..[1] = Total.[3] ( ) Cholesterol-(HDL+TG/5) HDL.[4].[5] (TG 400).[4].[6-10] NCEP-ATPIII (HRT) III
199 (2 ) 10 1389 -.. 352. 5015. 1 NCEP. ( ATP-III). 2 (%46/6) 164. 140/90 123/0318/54 mmhg.69/8511/51 mmhg 17/65 6/58. 21/4114/05 (-C. 1/70/8 ) NCEP. 3 NCEP 400 13 mg/dl.. 400. 4. 4/25 (C-) 15/87 (D-) TG. 5 Post Hoc D-.(P< C- 0/0001) Analysis 55 ) ( 65. ( 10 )... 717 (TC) (TG) (HDL). (). 400... NCEP-ATPIII. t-test. ANOVA. -. SPSS 16
... : 200 D- C-. r=0/95 P< 2 0/0001).(D- =(%95 C-). 200-26/15. D- C-. C- 40/83. 118/03. 116/76 (P< /0001) 0/38 (P< D- 0/0001) 0/19 53/37 113/99 29/31.. (Bland-Altman Difference Plat) -... 39/07 113/39 D- C- X (Bias) Y. NCEP -4/25 15/87 ( ) -35/34-4/88.(1) 25/38. 6 (n =352) -1 36 127 64 225 6/25 22 32/1 113 17/61 62 24/43 86 19/60 69 3/97 14 53/97 190 28/97 102 12/5 44 0/56 2
201 (2 ) 10 1389 -. NCEP -2 (n =352) 20/5 72 33/5 118 1/13 4 0 0 0/3 1 10/22 36 4/8 17 46/6 164 (BP 140/90 ) 77/55 273 (HDL< 40 mg/dl) HDL 2/84 10 ( 65 > 55> ) 43/46 153 ( 55 45) NCEP (-C ) -3 (n=352) NCEP 25/85 91 35/52 125 2 2 38/63 136 1 0-4 (n=339) 46/54 200/21 366 110 76/33 167/98 397 28 11/65 49/1 105 25 HDL 41/05 117/54 274 26,5 30/64 112/66 221 48 D- C- -5 (n=339) D- C- (mg/dl) TG -9/27 12/72 * --6/94 14/25 * -0/62 15/31 * 8/47 17/53 69 165 82 22 < 100 100-200 200-300 300-400 P< 0/05 * ANOVA 339.
... : 202 NCEP -6 (n=339) 160 130 100 < 130 N (%) N (%) N (%) (%14/74) 50 (%1/17) 4 (%6/48) 22 (%7/07)24 (%16/33) 52 (%3/24) 11 (%7/66) 26 (%4/42) 15 (%26/54) 90 (%3/24) 11 (%10/02) 34 (%13/27) 45 (%28/31) 96 (%6/78) 23 (%10/91) 37 (%10/61) 36 2 2 (%22/12) 75 (%0/88) 3 (%8/25) 28 (%12/97) 44 (%21/53) 73 (%1/76) 6 (%9/73) 33 (%10/02) 34 1 0 (%63/42) 215 (%5/30)18 (%24/77) 84 (%33/33) 113 (%65/19) 221 (%11/79) 40 (%28/31) 96 (%25/07) 85 - -1 (n=339)
203 (2 ) 10 1389 -. 100.. D- C- -2.(n=339). 130.. D- C-. 0/95. 0/96.[11] (Women Health Study)..[12] 0/97. 400 339. 400.(r=0/95) 200. -.
... : 204 :. V V ) ( V LP(a).[13]. IDL Li. LP(a) LP(a) (> 600 mg/l 301-600 mg/l 300 mg/l) ).(%21/4 %8/5 %4/1 LP(a).[16] 300 LP(a) LP(a). %4 LP(a) Mora.. D- C-. C- D- 200..[13-15]. C- D- De Cordova.[13] 0/97 0/89 mg/dl ( 4/88 ) 5. -.... 10 5 Mora.[12] 7 2 De Cordova 300 ) ( Nauk.[13].[14] Can. %14. ( ).[4 15]
205 (2 ) 10 1389 -...[14] mg/dl 400 Mora.[13]........ mg/dl 400 : -. D- (r=0/38) (r=0/19) C-....[14]....... mg/dl 130..[17].
... : 206..... 1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on etection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult TreatmentPanel III). JAMA 2001; 285:2486-97. 2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kammel WB. Incidence of coronary heart disease and lipoprotein levels: the Framingham study. JAMA 1986; 256:2835 8. 3. Cole TG, Ferguson CA, Gibson DW, Nowatzke WL, Bachorik PS, Ross JW. Optimization of beta-quantification methods for highthroughput applications. Clin Chem 2001; 47(4):712 21. 4. Nauck M, Warnick R, Rifai N. Methods for measurement of -cholesterol: a critical assessment of direct measurement by homogeneous assay versus calculation. Clin Chem 2002; 48: 236-54. 5. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurements of low-density lipoprotein cholesterol: executive summary. National Cholesterol Education Program Working Group on Lipoprotein Measurements. Clin Chem 1995; 41: 1414-20. - NCEP-ATP III.. -.. mg/dl 400.. 6. Branchi A, Rovellini A, Torri A, Sommariva D. Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients. Diabetes Care 1998; 21:1397 402. 7. Johnson R, McNutt P, MacMahon S, Robson R. Use of the Friedewald formula to estimate cholesterol in patients with chronic renal failure on dialysis. Clin Chem 1997;43:2183 4. 8. Bairaktari ET, Tzallas C, Kalientzidou M, Tselepis AD, et al. Evaluation of alternative calculation methods for determining lowdensity lipoprotein cholesterol in hemodialysis patients. Clinical Biochem 2004; 37: 937 40. 9. Matas C, Cabre M, La Ville A, Prats E, Joven J, Turner PR, et al. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clin Chem 1994; 40:404 6. 10. Legault C, Stefanick M, Miller V, Marcovina S, Schrott H. Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: the Postmenopausal Estrogen/Progestins Interventions (PEPI) trial. J Clin Epidemiol 1999; 52: 1187 95.
207 (2 ) 10 1389 -. 11. Can M, Acikgoz S, Mungan G, et al. Is direct method of low density lipoprotein cholesterol measurement appropriate for targeting lipid lowering therapy? Int J Cardiol Jan 2010; 142(1): 105-7. 12. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. Clin Chemistry 2009; 55(5): 888-94. 13. De Cordova CMM, Schneider CR, Juttel ID, de Cordova MM. Comparison of -Cholesterol Direct Measurement with the Estimate Using the Friedewald Formula in a Sample of 10,664 Patients. Arquivos Brasileiros de Cardiologia 2004; 83:282-87. 14. Nauck M, Rifai N. Analytical performance and clinical efficacy of three routine procedures for cholesterol measurement compared with the ultracentrifugation-dextran sulfate-mg (2+) method. Clin Chim Acta 2000; 294:77 92. 15. Yu HH, Ginsbrug GS, Harris N et al. Evaluation and clinical application of a direct low density lipoprotein cholesterol assay in normolipemic and hyperlipidemic adults. Am J Cardiol 1997; 80: 1295-99. 16. Li KM, Wilcken DE, Dudman NP. Effect of serum lipoprotein (a) on estimation of lowdensity lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994; 40: 571 3. 17. Scharnagl H, Nauck M, Wieland H, Marz W. The Friedewald formula underestimates cholesterol at low concentrations. Clin Chem Lab Med 2001; 39: 426 31.